Results 41 to 50 of about 73,193 (159)

Risk Factors that Impact Treatment with Oral Janus Kinase Inhibitors Among Adult Patients with Atopic Dermatitis: A Nationwide Registry Study

Acta Dermato-Venereologica
The European Medicines Agency recently limited the use of oral Janus kinase inhibitors in certain patient populations, including those with atopic dermatitis.
Ida Vittrup, David Thein, Simon Francis Thomsen, Alexander Egeberg, Jacob P. Thyssen   +4 more
doaj   +1 more source

A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib

BMC Infectious Diseases, 2019
Background Ruxolitinib is a highly potent janus kinase inhibitor that places its users at risk for various bacterial infections and viral reactivation.
Katya Prakash, Douglas Richman
doaj   +1 more source

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis

JK Science, 2022
Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signalling has been established to have pathophysiological role in multiple disease states, such as myeloproliferative neoplasms, rheumatoid arthritis, inflammatory bowel ...
Vishal R. Tandon, Annil Mahajan
doaj  

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Journal of Hematology & Oncology, 2017
Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis.
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W. N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Mark Jones, Deanna Kornacki, Kang Sun, Hagop Kantarjian, for the COMFORT-I investigators   +21 more
doaj   +1 more source

Negative patch test findings after initiation of upadacitinib: A case report

SAGE Open Medical Case Reports
Upadacitinib is a systemic Janus kinase inhibitor currently approved for the treatment of atopic dermatitis. Many patients with atopic dermatitis have a concomitant diagnosis of allergic contact dermatitis.
Meghan L McPhie, Melanie D Pratt, Mark G Kirchhof   +2 more
doaj   +1 more source

Modern Management Approaches for Alopecia Areata

Вопросы современной педиатрии
Alopecia areata is a chronic genetically determined inflammatory autoimmune disease damaging hair follicles and leading to temporary or persistent nonscarring hair loss.
Eduard T. Ambarchyan, Vladislav V. Ivanchikov, Anastasiya D. Alekseeva, Olga B. Gordeeva, Leyla S. Namazova-Baranova   +4 more
doaj   +1 more source

Baricitinib triggering a central nervous system inflammatory-demyelinating disease: A case report

Multiple Sclerosis Journal - Experimental, Translational and Clinical
Janus kinase inhibitors (JAKis), such as baricitinib, target the Janus kinase/signal transducers and activators of transcription pathway to regulate proinflammatory cytokines and T-helper cell activity, thereby reducing inflammation.
Rozita Khalili, Ahmad A. Toubasi, Meryim Poursheykhi, Francesca Bagnato   +3 more
doaj   +1 more source

Pulmonary arterial hypertension in interferonophaties: a case report and a review of the literature

Pulmonary Circulation, 2019
Background Pulmonary arterial hypertension consists in an increase of mean pulmonary arterial pressure (PAPm ≥ 25 mmHg), and may lead to right ventricular failure.
A. Trombetta, S. Ghirardo, S. Pastore, A. Tesser, E. Piscianz, A. Tommasini, M. Bobbo, A. Taddio   +7 more
doaj   +1 more source

Screening for Janus kinase-2 exon 12 mutations among Janus kinase-2 V617F-negative polycythemia vera suspected Iraqi patients

Iraqi Journal of Hematology
BACKGROUND: Diagnosis of myeloproliferative neoplasms including polycythemia vera (PV) has been greatly improved following the identification of driver mutations at exon 12 and exon 14 of the Janus Kinase 2 (JAK2) gene. There are limited academic studies
Mushtaq M. Khazeem, Alaa Fadhil Alwan
doaj   +1 more source

Machine learning-based prediction of response to Janus kinase inhibitors in patients with rheumatoid arthritis using clinical data

Frontiers in Immunology
ObjectiveRheumatoid arthritis (RA) is a chronic inflammatory disease with considerable heterogeneity in treatment response, leaving many patients unable to achieve remission or low disease activity. We aimed to develop a machine learning model to predict
Yeo-Jin Lee, Gyucheol Choi, Joongyeub Yeo, Jiyeong Baek, Heeju Choi, Minji Kim, Yong-Gil Kim, Bo Young Kim, Jamin Koo, Jamin Koo, Jamin Koo   +10 more
doaj   +1 more source